MAP Kinases and Prostate CancerReport as inadecuate

MAP Kinases and Prostate Cancer - Download this document for free, or read online. Document in PDF available to download.

Journal of Signal TransductionVolume 2012 2012, Article ID 169170, 9 pages

Review Article

Department of Cell Biology and Genetics, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain

Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, 28806 Madrid, Spain

Received 15 June 2011; Accepted 15 August 2011

Academic Editor: Fred Schaper

Copyright © 2012 Gonzalo Rodríguez-Berriguete et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The three major mitogen-activated protein kinases MAPKs p38, JNK, and ERK are signal transducers involved in a broad range of cell functions including survival, apoptosis, and cell differentiation. Whereas JNK and p38 have been generally linked to cell death and tumor suppression, ERK plays a prominent role in cell survival and tumor promotion, in response to a broad range of stimuli such as cytokines, growth factors, ultraviolet radiation, hypoxia, or pharmacological compounds. However, there is a growing body of evidence supporting that JNK and p38 also contribute to the development of a number of malignances. In this paper we focus on the involvement of the MAPK pathways in prostate cancer, including the less-known ERK5 pathway, as pro- or antitumor mediators, through their effects on apoptosis, survival, metastatic potential, and androgen-independent growth.

Author: Gonzalo Rodríguez-Berriguete, Benito Fraile, Pilar Martínez-Onsurbe, Gabriel Olmedilla, Ricardo Paniagua, and Mar Royuela



Related documents